Hong Kong and UK Forge Neurotech Alliance to Bridge Lab and Life

HONG KONG, SAR – May 18, 2026 – In a significant move to accelerate global progress in brain science, The Hong Kong Polytechnic University's (PolyU) Academy for Interdisciplinary Research (PAIR) has announced a strategic partnership with Cambridge NeuroWorks, a major UK neurotechnology initiative. The collaboration will launch with a new online seminar series designed to connect leading minds and foster breakthroughs, kicking off on May 27, 2026, with an inaugural address by world-renowned neuroscientist Prof. Edward Chang of the University of California.

This partnership unites two powerhouses of research and innovation from opposite sides of the globe, creating a formidable platform for advancing neurotechnology. The seminar series aims to serve as an international nexus for researchers, clinicians, industry professionals, and students, promising to spark new ideas and collaborations that could transform healthcare and quality of life for millions affected by neurological and mental health disorders.

A Strategic Alliance for Global Impact

The collaboration is built on the complementary strengths of both institutions. PAIR is recognized for its role in spearheading interdisciplinary research at PolyU, with a strong focus on brain health, biomedical engineering, and data science. The academy's mission is centered on translating complex research into solutions with tangible, real-world impact. This practical, application-driven approach makes it an ideal partner for an initiative focused on moving technology from the laboratory to the patient's bedside.

On the other side of the partnership is Cambridge NeuroWorks, a transformative UK initiative led by Cambridge University Health Partners (CUHP). It represents a concerted effort to build a national translational infrastructure for neurotechnology. Its core mission is to connect the entire ecosystem—from researchers and clinicians to entrepreneurs and patients—to streamline the often-long and arduous path from a groundbreaking idea to a widely available medical device or therapy. This new collaboration with PAIR aligns perfectly with PolyU's broader international strategy, which emphasizes global engagement and the application of diverse knowledge to solve pressing societal challenges in health and wellness.

The Engine Room: ARIA and Cambridge's Bold Vision

Powering the Cambridge NeuroWorks initiative is the Advanced Research and Invention Agency (ARIA), the UK’s high-risk, high-reward R&D funding agency. ARIA's involvement signals a commitment to funding radical, potentially disruptive ideas that traditional funding bodies might overlook. This multi-million-pound, three-year endeavor is a key part of ARIA’s strategy to unlock scientific breakthroughs that can benefit everyone.

Specifically, Cambridge NeuroWorks is designated as an "Activation Partner" within ARIA's "Scalable Neural Interfaces" program. This is backed by substantial government investment, including a £69 million "Precision Neurotechnologies" program and a £50 million "Massively Scalable Neurotechnologies" program. The latter is explicitly focused on finding innovative ways to deliver neurotechnologies to the brain without requiring invasive surgery, a major hurdle in the field.

The strength of Cambridge NeuroWorks is further amplified by its nine founding partners, a consortium that includes the University of Cambridge, the Babraham Research Campus, the Milner Therapeutics Institute, the Maxwell Centre, and several university departments and NHS trusts. This diverse coalition provides an unparalleled concentration of expertise in engineering, psychiatry, clinical medicine, and commercialization, creating a fertile environment for nurturing neurotechnology from its earliest stages.

Kicking Off with a Pioneer: The Significance of Edward Chang

The choice of Prof. Edward Chang as the inaugural speaker for the seminar series is highly symbolic of the collaboration's ambitions. A distinguished neurosurgeon and scientist at the University of California, San Francisco (UCSF), Prof. Chang is a leading figure in the field of brain-computer interfaces (BCIs). His work exemplifies the translational focus that both PAIR and Cambridge NeuroWorks champion.

Prof. Chang is renowned for his pioneering research on the neural code of speech. As co-director of the Center for Neural Engineering and Prostheses, a joint UCSF-UC Berkeley initiative, he has been at the forefront of developing biomedical technologies to restore function for patients with severe neurological disabilities. His most celebrated work involves the creation of a speech neuroprosthesis—a BCI that can translate a paralyzed person's brain activity directly into synthesized speech in near real-time. This technology represents a quantum leap for individuals who have lost the ability to communicate, moving beyond slow, text-based interfaces to a more natural and fluid form of expression.

Featuring a scientist whose work so perfectly embodies the journey from fundamental neuroscience to life-changing technology sends a clear message: this series is about more than just academic discussion. It is about showcasing and inspiring the kind of work that directly leads to healthcare solutions.

Accelerating Neurotechnology from Lab to Life

The partnership is poised to inject new momentum into several critical areas of neurotechnology. The global market for these technologies is projected to reach tens of billions of dollars within the next decade, driven by an aging population, the rising prevalence of neurological disorders, and rapid technological advancements. While North America has traditionally dominated the market, the Asia Pacific region is a rapidly growing hub for innovation.

Fields likely to see significant benefit from this cross-continental exchange include the development of next-generation BCIs and neural prosthetics for restoring movement and communication. Furthermore, the collaboration could accelerate progress in miniaturized brain implants and neuromodulation devices used to treat conditions like depression, chronic pain, and epilepsy. Another key area is neurodiagnostics, where AI-driven tools, advanced imaging, and portable monitoring devices are revolutionizing how brain disorders are detected and managed.

By creating a digital bridge between the thriving research ecosystems of Hong Kong and Cambridge, the seminar series lowers barriers to collaboration. It establishes a dynamic, accessible platform for sharing cutting-edge findings and fostering the interdisciplinary dialogue necessary to solve complex neuroscientific challenges. This digital frontier of academia not only makes specialized knowledge more globally accessible but also cultivates the cross-pollination of ideas that is essential for true innovation, ultimately aiming to shorten the timeline from scientific discovery to clinical application.